





## From the INNOVATION LEADER in Thrombosis & Hemostasis

More information on HYPHEN BioMed and product catalog is available at : www.hyphen-biomed.com



1

# HYPHEN BioMed 155 rue d'Eragny, 95000 Neuville-sur-Oise, France • Tel: +33 (0)1.34.40.65.10 • info@hyphen-biomed.com • www.hyphen-biomed.com

# Chromogenic FXIII Activity assay **BIOPHENTM FXIII**

# **Excellent Linearity**



# **Chromogenic FXIII Activity Assay: BIOPHENTM FXIII**

### Chromogenic activity assay as First-line test for measuring FXIII: congenital or acquired deficiencies; FXIII substitutive therapy.

### Convenient, and Economical with extended stability:

- Stable after opening:
- 5 days onboard\*, 7 days at 2-8°C, 2 days at 18-25°C 2 months when frozen <20°C
- Long shelf life at 2-8°C in original packaging

\* example on Sysmex CS-series

### Specific and reliable assay:

- Specificity verified on FXIII deficient plasma: FXIII % < LOD
- No interference of plasma contents and anticoagulants: Hemoglobin, Bilirubin, Intralipids, Fibrinogen, Ammonium, Heparins, DOACs

#### Extended measurement range useful to explore various contexts:

- Extended measurement range of 5-300% (with redilution)
- High specificity verified at very low concentration <15%

#### Automatable and standardised:

- Automated: validated application guide on Sysmex CS-series Calibrators & Controls
- traceable to WHO International Standard

### Reagent

FXIII in the tested sample, is converted into activated Factor XIII (FXIIIa) by the combined effect of thrombin and calcium<sup>2</sup>. Soluble fibrin, also generated by the action of thrombin, accelerates the reaction while an antipolymerization peptide avoids the clot formation. FXIIIa transglutaminase activity between a synthetic peptide substrate and glycine ethyl ester (GEE) leads to the formation of ammonium (NH4<sup>+</sup>). Ammonium is then assayed through the reaction of glutamate dehydrogenase (GLDH) converting NADPH into NADP+, in the presence of ammonium and alpha ketoglutarate. The conversion of NADPH into NADP<sup>+</sup> can be detected at 340 nm, and the slope of the absorbance decrease at 340nm is directly proportional to the concentration of FXIII in the tested sample.



#### Reference

- 1. Kohler HP et al. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost. 2011;9:1404-6
- 2. Karpati L et al. A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. Clin Chem. 2000
- 3. Dorgalaleh A et al. Laboratory Diagnosis of Factor XIII Deficiency in Developing Countries: An Iranian Experience. Laboratory Medicine. 2016;47:3:220-226

### **FXIII and its deficiency**

FXIII is a protransglutaminase of tetramer structure (FXIII-A<sub>2</sub>B<sub>2</sub>), with the A subunit being the functional form. When activated to FXIIIa, it has a major role in the final stage of blood coagulation, serving as the fibrin stabilizing factor. FXIII deficiency may be congenital, or acquired as a result of hyperconsumption or presence of autoantibodies. Low FXIII levels have been associated with bleeding complications, eg in situations such as trauma or surgery. FXIII is also involved in various other processes such as wound healing and maintenance of pregnancy.<sup>1,2</sup>

Assaying FXIII activity in human plasma may help in the diagnosis of congenital or acquired FXIII deficiencies. Inherited FXIII-A deficiency is a rare bleeding disorder that affects one individual out of 1-3 million and prophylactic replacement therapy is mandatory if the diagnosis of severe congenital FXIII deficiency is confirmed.<sup>1</sup> Because FXIII (as a coagulation factor) is not involved in the formation of an early unstable clot, all routine coagulation tests, including bleeding time (BT), prothrombin time (PT), and activated partial thromboplastin time (APTT), show normal results in FXIII.<sup>3</sup>

#### Expected FXIII activity values and antigen concentrations in FXIII deficiencies<sup>1</sup>

Deficiency		Plasma				Platelet		
			FXIII activity	FXIII-A <sub>2</sub> B <sub>2</sub> Ag	FXIII-A Ag	FXIII-B Ag	FXIII activity	FXIII-A Ag
Inherited	FXIII-A deficiency	Type I (quantitative)	$\downarrow \downarrow \downarrow \downarrow$	$\uparrow \uparrow \uparrow \uparrow$	$\downarrow \downarrow \downarrow \downarrow$	>30%	$\downarrow \downarrow \downarrow \downarrow$	$\downarrow \downarrow \downarrow \downarrow$
		Type II (qualitative)	$\downarrow \downarrow \downarrow \downarrow$	↓-N	↓-N	>30%	$\downarrow \downarrow \downarrow \downarrow$	↓-N
	FXIII-B defici	ency	$\uparrow \uparrow$	$\uparrow \uparrow \uparrow$	$\downarrow\downarrow$	$\downarrow \downarrow \downarrow \downarrow$	N	N
Autoantibody against FXIII	Anti-FXIII-A	Neutralizing	$\downarrow \downarrow \downarrow \downarrow$	<b>↓-</b> N	√-N	>30%	N	N
		Non- neutralizing	$\downarrow \downarrow \downarrow \downarrow$	$\downarrow \downarrow \downarrow \downarrow$	$\downarrow \downarrow \downarrow \downarrow$	>30%	N	N
	Anti-FXIII-B		$\downarrow \downarrow \downarrow \downarrow$	$\uparrow \uparrow \uparrow$	$\downarrow \downarrow \downarrow \downarrow$	$\downarrow \downarrow \downarrow \downarrow$	N	N
Other aquired	deficiencies		$\downarrow$	$\downarrow$	$\downarrow$	<b>↓</b> -N	NA	NA

 $\downarrow \downarrow \downarrow \downarrow$ , highly decreased activity/concentration usually below 3%;

 $\downarrow \downarrow$ , considerably decreased activity/concentration, usually 5–10%;

 $\downarrow$ , slightly decreased activity, usually 20–70%;

N, normal; NA, non-applicable

### **Performance characterstics**

#### Precision

Control	Intra-assay				Inter-assay			
Control	Ν	Mean %	CV %	SD	Ν	Mean %	CV %	
Normal	40	102.3	2.7	2.8	30	102.6	1.5	
Abnormal	40	28.8	4.9	1.4	30	31.2	1.9	

The inter -assay variability is evaluated with laboratory controls over 5 days, 2 series per day and 3 repetitions in each series for each level of control.

#### **Range of measurement:**

Measurement Principle	Calibration Range		
Chromogenic	Concentration of FXIII (%)	0-165*	*
method	Raw values (OD/min)	0.0017 - 0.0334**	

### **Ordering information**

	Product name	Kit presentation	Ref N°:	Status
Chromogenic assay for quantitation of FXIII activity	BIOPHEN™ Factor XIII	R1: Thrombin Reagent (3 x 4mL) R2: Detection Reagent (3 x 5 mL)	227005	CE-IVD

#### Additional products required:

	Product name	Ref N°:	Status
Calibrator	BIOPHEN <sup>™</sup> Plasma Calibrator	222101	CE-IVD
Controls	BIOPHEN™ Normal Control Plasma BIOPHEN™ Abnormal Control Plasma	223201 223301	CE-IVD CE-IVD
Buffer	Physiological Saline Buffer	-	-

#### **Overview of ISTH SSC recommended** algorithm for diagnosis of FXIII deficiencies<sup>1</sup>



#### **Example of calibration curve:**



Values dependent on the calibrator.

SD

1.5

0.6

\* These values are given for information and may vary from one

batch to another and from one analyzer to another

#### **Related products:**

	Product name	Ref N°:	Status		
ELISA	ZYMUTEST <sup>™</sup> Factor XIII-A	RK034A (On-demand)	RUO		
Deficient Plasma	FXIII Deficient Plasma	DP200A/K	RUO		

Please contact your local distributor found on our website: www.hyphen-biomed.com

#### 3